Alefacept for psoriasis and psoriatic arthritis. - Wikidata - wikimedia - TriplyDB

Alefacept for psoriasis and psoriatic arthritis.

Alefacept for psoriasis and psoriatic arthritis.

http://www.wikidata.org/entity/Q36292648

about

Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasis.

P2860

Q43042832-94EF1BD4-73AE-4455-A9E5-B2A102A11883

P2860

Alefacept for psoriasis and psoriatic arthritis.

http://www.wikidata.org/entity/Q36292648

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Alefacept for psoriasis and psoriatic arthritis.

@ast

Alefacept for psoriasis and psoriatic arthritis.

@en

type

label

Alefacept for psoriasis and psoriatic arthritis.

@ast

Alefacept for psoriasis and psoriatic arthritis.

@en

prefLabel

Alefacept for psoriasis and psoriatic arthritis.

@ast

Alefacept for psoriasis and psoriatic arthritis.

@en

P1433

Q36292648-A50C3F69-347F-48CE-ABFE-F4DDA8789FC6

P1476

Q36292648-A597C024-68FF-4B81-9935-D5AA53297B9B

P2093

Q36292648-B384CAB9-0EB7-4FFA-8171-5055D3478EB1

P2860

Q36292648-1AA8C4CE-AD09-4171-A892-EF3A76B010DE

Q36292648-68CC8487-18D1-4DAE-8A8D-58E3E11466C1

Q36292648-9311247E-D84F-48A8-9C36-139AF78424CB

Q36292648-A8A7193F-DDA7-4D83-8D72-55BEBEA1F913

Q36292648-AAF992C5-A323-4E0A-BA83-A1FBEC5830CB

Q36292648-BBBC0DC5-D8D1-4A6E-A16B-D606485101A1

Q36292648-C722DE6F-DE30-43BF-9B68-C2CDADB43C4C

Q36292648-C923CB4C-8F09-4804-A223-86BB871F323A

P304

Q36292648-39B798DF-2A42-4C77-9322-F4BBA6218FEE

P31

Q36292648-AF181EC6-48C4-43B1-8FED-37AB767246CF

P356

Q36292648-2112CFE1-E94C-433F-BCA8-589E041AB992

P407

Q36292648-B69189F8-7C76-4E3B-AF38-D74CF5FCC7B2

P478

Q36292648-D324F658-F127-4CCF-AD5A-9657197A4A4B

P577

Q36292648-E528AD15-CB68-4163-B2D9-AEA623B25A8B

P5875

Q36292648-93312282-D001-4511-8FCA-5C60A419FB87

P698

Q36292648-99AF717B-E99C-4E07-9BBA-1802D775E2EB

P932

Q36292648-922D2694-5AD3-41F1-8D0A-2640AEDF7BB1

P356

ARD.2005.042655

P1433

Annals of the Rheumatic Diseases

P1476

Alefacept for psoriasis and psoriatic arthritis.

@en

P2093

A B Gottlieb

http://www.w3.org/2001/XMLSchema#string

P2860

Severe psoriasis--oral therapy with a new retinoid.

The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system.

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.

CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

Eruptive pseudoangiomatosis caused by an insect bite.

P304

iv58-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2005.042655

http://www.w3.org/2001/XMLSchema#string

P407

P478

64 Suppl 4

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7527897

http://www.w3.org/2001/XMLSchema#string

P698

16239390

http://www.w3.org/2001/XMLSchema#string

P932

1766916

http://www.w3.org/2001/XMLSchema#string